Synthimed Labs

Synthimed Labs is an India-based pharmaceutical company that specializes in the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and finished dosage forms. Formed in 2023 by the India Resurgence Fund (a joint venture between Piramal Group and Bain Capital), the company significantly expanded its operations by acquiring the API and CRAMS business of Ind-Swift Laboratories. Synthimed operates three state-of-the-art manufacturing facilities and a dedicated R&D center in Mohali, holding approvals from global regulatory authorities including the USFDA, EDQM, and PMDA. The company offers a diverse portfolio of over 34 APIs across 19 therapeutic categories, with a particularly strong market position in macrolide antibiotics and cardiovascular treatments. Serving over 1,000 customers in more than 70 countries, Synthimed Labs focuses on providing high-quality synthetic chemistry services and contract manufacturing to the global pharmaceutical industry.